Otonomy has chalked up its second clinical trial failure in the space of a few months, the latest in a mid-stage study of a treatment for hearing loss, and the biotech has now been forced i
Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category.
The team at Oxford University behind the landmark RECOVERY trial of COVID-19 therapies now has monkeypox in its sights, with a study that will see if Siga Technologies' smallpox drug Tpoxx
Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xan
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.